Impact of molecular biology studies on the understanding of brain tumors in childhood

Current Oncology Reports

Volumn 14, Issue 2, 2012, Pages 206-212

  Nageswara Rao, Amulya A ^a   Packer, Roger J ^b,c  

^a MAYO CLINIC   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Embryonal tumors; Ependymoma; High grade glioma; Low grade glioma; Management; Medulloblastoma; Molecular pathology; Pediatric brain tumors

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR RECEPTOR; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; INTERLEUKIN 13 RECEPTOR ALPHA2; NEUROTROPHIN 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; PROTEIN PATCHED 1; SMOOTHENED PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR OTX2; TRANSCRIPTION FACTOR SNF; TRANSCRIPTION FACTOR SNF5; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; BRAIN TUMOR; CANCER CLASSIFICATION; CANCER PROGNOSIS; CARCINOGENESIS; CHILDHOOD CANCER; CHROMOSOME 17Q; CHROMOSOME 6; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC PROCEDURE; EPENDYMOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZATION; ISOCHROMOSOME; KARYOTYPING; MEDULLOBLASTOMA; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE MYC; PATIENT CARE; PILOCYTIC ASTROCYTOMA; PROTEIN EXPRESSION; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOID TUMOR; RISK ASSESSMENT; ADOLESCENT; CHILD; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; INFANT; MALE; METABOLISM; METHODOLOGY; PRESCHOOL CHILD; TERATOMA;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION; GLIOMA; HUMANS; INFANT; MALE; MOLECULAR BIOLOGY; RHABDOID TUMOR; TERATOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84860856593     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0214-3     Document Type: Article

References (81)

1. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL website: wwwcbtrusorg (2011).
2. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res. 2010;174 (6): 840-50.
3. Turner CD, Rey-Casserly C, Liptak CC, et al. Late effects of therapy for pediatric brain tumor survivors. J Child Neurol. 2009;24 (11): 1455-63.
4. Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 2007;6 (12): 1073-85. (Pubitemid 350116703)
5. Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg. 2003;39 (2): 60-7. (Pubitemid 36829097)
6. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114 (2): 97-109. (Pubitemid 47103521)
7. Leary SE, Zhou T, Holmes E, et al. Histology predicts a favorable outcome in young children with desmoplastic medulloblastoma: a report from the children's oncology group. Cancer. 2011;117 (14): 3262-7.
8. Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international metaanalysis. Journal of clinical oncology: official journal of theAmerican Society of Clinical Oncology. J Clin Oncol. 2010;28 (33): 4961-8.
9. von Hoff K, Hartmann W, von Bueren AO, et al. Large cell/ anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors. Pediatr Blood Cancer. 2010;54 (3): 369-76.
10. Giangaspero F, Wellek S, Masuoka J, et al. Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol. 2006;112 (1): 5-12. (Pubitemid 43942157)
11. Lamont JM, McManamy CS, Pearson AD, et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clinical cancer research: an official journal of the American Association for Cancer Research. Clin Cancer Res. 2004;10 (16): 5482-93. (Pubitemid 39100486)
12. Pan E, Pellarin M, Holmes E, et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clinical cancer research: an official journal of the American Association for Cancer Research. Clin Cancer Res. 2005;11 (13): 4733-40. (Pubitemid 41557192)
13. Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. J Clin Oncol. 2009;27 (10): 1627-36.
14. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet. 2009;41 (4): 465-72.
15. Stearns D, Chaudhry A, AbelTW, et al. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res. 2006;66 (2): 673-81. (Pubitemid 43165929)
16. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004;63 (5): 441-9. (Pubitemid 38669665)
17. Pfaff E, Remke M, Sturm D, et al. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. J Clin Oncol. 2010;28 (35): 5188-96.
18. Mendrzyk F, Radlwimmer B, Joos S, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. J Clin Oncol. 2005;23 (34): 8853-62. (Pubitemid 46211532)
19. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol. 2002;12 (1): 36-44. (Pubitemid 33131360)
20. Di C, Liao S, Adamson DC, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by alltrans retinoic acid. Cancer Res. 2005;65 (3): 919-24. (Pubitemid 40216452)
21. Crawford JR, Rood BR, Rossi CT, et al. Medulloblastoma associated with novel PTCH mutation as primary manifestation of Gorlin syndrome. Neurology. 2009;72 (18): 1618.
22. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta neuropathologica 2011: 121 (3): 381- 396. This study describes the clinicopathologic data of the SHH, WNT, and SHH/WNT molecular subgroups of medulloblastoma based on a clinical trial cohort.
23. Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/ SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer. 2000;27 (1): 44-51.
24. McLaughlin MR, Gollin SM, Lese CM, et al. Medulloblastoma and glioblastoma multiforme in a patient with Turcot syndrome: a case report. Surg Neurol. 1998;49 (3): 295-301. (Pubitemid 28106875)
25. Dahmen RP, Koch A, Denkhaus D, et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res. 2001;61 (19): 7039-43. (Pubitemid 32946492)
26. McMahon AP, Bradley A. The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. Cell. 1990;62 (6): 1073-85.
27. Hayden MA, Akong K, Peifer M. Novel roles for APC family members and Wingless/Wnt signaling during Drosophila brain development. Dev Biol. 2007;305 (1): 358-76. (Pubitemid 46589426)
28. Fattet S, Haberler C, Legoix P, et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. The Journal of pathology 2009: 218 (1): 86-94. CTNNB1-mutated tumours represent a distinct molecular subgroup of medulloblastomas with favourable outcome.
29. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010;468 (7327): 1095-9.
30. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. J Clin Oncol. 2006;24 (12): 1924-31. (Pubitemid 46638992)
31. Yokota N, Nishizawa S, Ohta S, et al. Role of Wnt pathway in medulloblastoma oncogenesis. International journal of cancer Journal international du cancer. Int J Cancer. 2002;101 (2): 198-201. (Pubitemid 34970914)
32. Ellison DW, Onilude OE, Lindsey JC, et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. J Clin Oncol. 2005;23 (31): 7951-7. (Pubitemid 46657395)
33. de Bont JM, Packer RJ, Michiels EM, et al. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol. 2008;10 (6): 1040-60.
34. Xu P, Pu PY, Kang CS, et al. Differential expression of Notch1 and Notch2 in astrocytoma and medulloblastoma. Zhonghua bing li xue za zhi Chinese journal of pathology. 2008;37 (7): 450-3.
35. Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 2007;67 (5): 1879-82.
36. Gilbertson RJ, Pearson AD, Perry RH, et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer. 1995;71 (3): 473-7.
37. Gilbertson RJ, Clifford SC. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet. 2003;35 (3): 197-8. (Pubitemid 37363165)
38. Grotzer MA, Janss AJ, Phillips PC, et al. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr. 2000;212 (4): 196-9. (Pubitemid 30650554)
39. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011: 29 (11): 1408-1414. Four molecular subgroups of medulloblastoma were identified using an integrated genomic approach and the use of immunohistochemistry for classifying the four subgroups has been described.
40. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3 (8): e3088.
41. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. J Clin Oncol. 2011;29 (11): 1424-30.
42. Curran EK, Sainani KL, Le GM, et al. Gender affects survival for medulloblastoma only in older children and adults: a study from the Surveillance Epidemiology and End Results Registry. Pediatr Blood Cancer. 2009;52 (1): 60-4.
43. Biegel JA. Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus. 2006;20 (1): E11.
44. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg. 1996;85 (1): 56-65. (Pubitemid 26195038)
45. Biegel JA, Kalpana G, Knudsen ES, et al. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/ rhabdoid tumors. Cancer Res. 2002;62 (1): 323-8. (Pubitemid 34074022)
46. Versteege I, Sevenet N, Lange J, et al. Truncatingmutations of hSNF5/ INI1 in aggressive paediatric cancer. Nature. 1998;394 (6689): 203-6. (Pubitemid 28325977)
47. Biegel JA, Tan L, Zhang F, et al. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. Clin Cancer Res. 2002;8 (11): 3461-7. (Pubitemid 35340722)
48. Janson K, Nedzi LA, David O, et al. Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer. 2006;47 (3): 279-84. (Pubitemid 44148044)
49. Biegel JA, Fogelgren B, Wainwright LM, et al. Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor. Genes Chromosomes Cancer. 2000;28 (1): 31-7. (Pubitemid 30176760)
50. Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroids plexus carcinoma. J Neuropathol Exp Neurol. 2005;64 (5): 391-7. (Pubitemid 40629129)
51. Haberler C, Laggner U, Slavc I, et al. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol. 2006;30 (11): 1462-8. (Pubitemid 44655483)
52. Hasselblatt M, Gesk S, Oyen F, et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol. 2011;35 (6): 933-5.
53. Schneppenheim R, Fruhwald MC, Gesk S, et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet. 2010;86 (2): 279-84.
54. Birks DK, Kleinschmidt-DeMasters BK, Donson AM, et al. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol. 2010;20 (1): 140-50.
55. Gessi M, Giangaspero F, Lauriola L, et al. Embryonal tumors with abundant neuropil and true rosettes: a distinctive CNS primitive neuroectodermal tumor. Am J Surg Pathol. 2009;33 (2): 211-7.
56. Wang Y, Chu SG, Xiong J, et al. Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with a focal amplification at chromosome 19q13.42 locus: further evidence of two new instances in China. Neuropathology : official journal of the Japanese Society of Neuropathology 2011.
57. Pfister S, Remke M, Castoldi M, et al. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol. 2009;117 (4): 457-64.
58. Korshunov A, Remke M, Gessi M, et al. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol. 2010;120 (2): 253-60.
59. Cheng Y, Pang JC, Ng HK, et al. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas. Histopathology. 2000;37 (5): 437-44.
60. Sanoudou D, Tingby O, Ferguson-Smith MA, et al. Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br J Cancer. 2000;82 (6): 1218-22. (Pubitemid 30128882)
61. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in lowgrade astrocytomas. J Clin Invest. 2008;118 (5): 1739-49. (Pubitemid 351632377)
62. Sievert AJ, Jackson EM, Gai X, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density singlenucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19 (3): 449-58.
63. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta neuropathologica 2011: 121 (3): 397-405. This study shows a high association of the BRAFV600E mutation in pleomorphic xanthoastrocytomas, gangliogliomas, and extra-cerebellar pilocytic astrocytomas. BRAFV600E mutation may play a role as a potential diagnostic marker and may pave the way for use of targeted therapeutics in future clinical trials with these tumors.
64. Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011;121 (6): 763-74.
65. Viana-Pereira M, Lopes JM, Little S, et al. Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer research 2008: 28 (2A): 913-920. (Pubitemid 351578937)
66. Liang ML, Ma J, Ho M, et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol. 2008;87 (3): 247-53.
67. Bax DA, Gaspar N, Little SE, et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clinical cancer research: an official journal of the American Association for Cancer Research. Clin Cancer Res. 2009;15 (18): 5753-61.
68. Rood BR, MacDonald TJ. Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. J Neurooncol. 2005;75 (3): 267-72. (Pubitemid 43019481)
69. Thorarinsdottir HK, Santi M, McCarter R, et al. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clinical cancer research: an official journal of the American Association for Cancer Research. Clin Cancer Res. 2008;14 (11): 3386-94.
70. Nakamura M, Shimada K, Ishida E, et al. Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol. 2007;9 (2): 113-23. (Pubitemid 46580313)
71. Broniscer A, Baker SJ, West AN, et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. J Clin Oncol. 2007;25 (6): 682-9. (Pubitemid 350002924)
72. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006;105 (5 Suppl): 418-24. (Pubitemid 44954773)
73. Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. J Clin Oncol. 2010;28 (18): 3061-8.
74. Antonelli M, Buttarelli FR, Arcella A, et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol. 2010;99 (2): 209-15.
75. Fassan M, Tassone E, Onisto M, et al. MGMT promoter methylation in pediatric high-grade gliomas. Child's nervous system: ChNS: official journal of the International Society for Pediatric Neurosurgery. Childs Nerv Syst. 2011;27 (1): 7-8.
76. Lee JY, Park CK, Park SH, et al. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2011.
77. Gilbertson RJ, Hill DA, Hernan R, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clinical cancer research: an official journal of the American Association for Cancer Research. Clin Cancer Res. 2003;9 (10 Pt 1): 3620-4. (Pubitemid 37169226)
78. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. J Clin Oncol. 2010;28 (8): 1337-44.
79. Joshi BH, Puri RA, Leland P, et al. Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. Neuro Oncol. 2008;10 (3): 265-74.
80. Barrow J, Adamowicz-Brice M, Cartmill M, et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol. 2011;13 (2): 212-22.
81. Monje M, Mitra SS, Freret ME, et al. Hedgehog-responsive candidate ell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA. 2011;108 (11): 4453-8